Anticancer agents drive from <i>Bacillus thuringiensis</i>

Cancer is one of the most fatal diseases that rarely any cancer patient survives from it. Cancer affect different ages and sex causing great humanity losses reaches up to 100,000 patient / year according to the recent statistical analysis. It also, affects different tissues causing irreversible cytopathological changes result in highly undifferentiated cells that hard to be controlled or eradicated. The chemotherapy, radiotherapy and surgical interference still used in elimination of the disease since decades however both radiotherapy and chemotherapy did not prove acceptable success in the cancer treatment until now, unfortunately the surgical interference could not be more helpful as it did not overcome the malignancy metastasis which gets back wilder after surgical interference due to metastasis. So, it was sound good to use the biological anti-malignancy agents in eradication of cancer cells. Biological anticancer agents provide a confident success in cancer therapy which includes many microbial metabolites derived from the members of Family Bacillacae such as Bacillus thuringiensis, Bacillus polymixa and other members explored recently in the Saudi environment. For example in a previous studies recorded by us some serovars of Bacillus thuringiensis enzymatically activated parasporal inclusion proteins proved a potent anti-malignancy effect on acute lymphocyte leukemia, lung carcinoma, larynx carcinoma and uterine cervix carcinoma in vitro and a great result was recorded in vivo on the Ehirlch Acites Carcinoma. These biological anti-malignancy agents had a selective direct cytotoxic effect on cancer cells in addition to improving the immune status (immunomodulation) which helps in destruction of the cancer cells and dysfunction of their metastasis properties.